Activ Surgical today received a $15 million extension to its Series B financing round, bringing its total Series B to $60 million.
Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, led the Series B extension, which also had participation from existing investors. The $15 million investment announced today adds to the initial $45 million Boston-based Activ raised in September 2021.
Activ Surgical develops augmented reality (AR)-based and artificial intelligence (AI)-driven surgery technology. It designed the ActivEdge surgical intelligence platform for reducing unintended and preventable surgical errors by improving decision-making through AI, as well as the ActivSight imaging module for upgrading existing operating room equipment by serving as the “eyes” of the ActivEdge platform.
ActivSight received FDA clearance last year and is part of pilot sites at a number of hospital networks in the U.S. and Europe. It is available now through a limited market release and will be broadly available in 2022.
“Hikma Ventures’ investment in Activ Surgical comes at a critical inflection point in the company’s history as our team is hard at work preparing for the global launch of our ActivSight imaging module later this year,” Activ Surgical CEO Todd Usen said in the release. “This investment will allow us to scale our business quickly and add resources needed to ensure a successful rollout of the ActivSight imaging module, helping to fulfill our mission to empower surgeons’ intraoperative decision-making and, ultimately, enhance patient safety.”